{"generic":"Follicle Stimulating Hormone\/Luteinizing Hormone","drugs":["Follicle Stimulating Hormone\/Luteinizing Hormone","Menopur","Pergonal","Repronex"],"mono":{"0":{"id":"367260-s-0","title":"Generic Names","mono":"Follicle Stimulating Hormone\/Luteinizing Hormone"},"1":{"id":"367260-s-1","title":"Dosing and Indications","sub":{"0":{"id":"367260-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Assisted reproductive technology:<\/b> (Menopur(R)), initial dose, 225 international units SUBQ daily beginning cycle day 2 or 3; adjust dose based on ovarian response on day 5; do not adjust dose more often than every 2 days and do not adjust by more than 150 international units per adjustment; continue until adequate follicular development and then administer human chorionic gonadotropin; MAX dose, 450 international units\/day; MAX duration of treatment, 20 days<\/li><li><b>Assisted reproductive technology:<\/b> (Menopur(R), when administered together with urofollitropin) initial dose, Menopur(R) 150 international units plus urofollitropin 75 international units SUBQ OR Menopur(R) 75 international units plus urofollitropin 150 international units SUBQ daily beginning cycle day 2 or 3; adjust dose based on ovarian response on day 5; do not adjust dose more often than every 2 days and do not adjust by more than 150 international units per adjustment; continue until adequate follicular development and then administer human chorionic gonadotropin; MAX combined dose of urofollitropin and Menopur(R), 450 international units\/day; MAX duration of treatment, 20 days<\/li><li><b>Assisted reproductive technology:<\/b> (Repronex(R)), initial dose, 225 international units SUBQ or IM; adjust dose based on ovarian response; do not adjust dose more often than every 2 days and do not adjust by more than 75 to 150 international units per adjustment; continue until adequate follicular development and then administer human chorionic gonadotropin; MAX dose, 450 international units\/day; MAX duration of treatment, 12 days<\/li><li><b>Ovulation induction:<\/b> (Repronex(R)) initial dose, 150 international units IM or SUBQ daily for 5 days; base subsequent doses on patient response and clinical monitoring, including serum estradiol levels and vaginal ultrasound; do not adjust dose more often than every 2 days and do not adjust by more than 75 to 150 international units per adjustment; MAX dose, 450 international units\/day; MAX duration of treatment, 12 days<\/li><\/ul>"},"1":{"id":"367260-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness have not been established in pediatric patients "},"3":{"id":"367260-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Assisted reproductive technology<\/li><li>Ovulation induction<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Polycystic ovary syndrome<br\/>"}}},"3":{"id":"367260-s-3","title":"Contraindications\/Warnings","sub":[{"id":"367260-s-3-9","title":"Contraindications","mono":"<ul><li>bleeding, abnormal and with underdetermined origin<\/li><li>follicle stimulating hormone level high, indicating primary ovarian failure<\/li><li>hypersensitivity to menotropins<\/li><li>infertility of any cause other than anovulation, unless patient is candidate for in vitro fertilization<\/li><li>intracranial lesion, organic (eg, pituitary tumor)<\/li><li>non-gonadal endocrinopathies, uncontrolled (ie, thyroid, adrenal, or pituitary disorders) (Menopur(R))<\/li><li>ovarian cysts or enlargement not due to polycystic ovary syndrome<\/li><li>pregnancy<\/li><li>sex hormone dependent tumors of the reproductive tract and accessory organs (Menopur(R))<\/li><li>tumors of pituitary gland or hypothalamus (Menopur(R))<\/li><li>uterine bleeding, abnormal, origin undetermined<\/li><\/ul>"},{"id":"367260-s-3-10","title":"Precautions","mono":"<ul><li>abortion, spontaneous, may occur (Menopur(R))<\/li><li>congenital malformations may occur; increased risk with assisted reproductive technology (Menopur(R))<\/li><li>ectopic pregnancy may occur; monitoring recommended (Menopur(R))<\/li><li>hypersensitivity and anaphylactic reactions have been reported (Repronex(R))<\/li><li>multiple pregnancies may occur<\/li><li>ovarian enlargement may occur; monitoring recommended; withhold hCG if ovaries are abnormally enlarged on last day of treatment<\/li><li>ovarian enlargement, significant; increased risk of hemoperitoneum from ruptured ovarian cysts; prohibit intercourse (Menopur(R))<\/li><li>ovarian hyperstimulation syndrome (OHSS) has been reported; increased risk of injury to ovary; monitoring recommended; withhold hCG if evidence OHSS developing prior to hCG administration; discontinue use if serious OHSS occurs<\/li><li>ovarian neoplasm, both benign and malignant, may occur (Menopur(R))<\/li><li>ovarian torsion has been reported; may be related to OHSS, pregnancy, prior abdominal surgery, ovarian cyst, polycystic ovaries; or past history of ovarian torsion (Menopur(R))<\/li><li>pulmonary complications, serious, including atelectasis and acute respiratory distress syndrome, have been reported<\/li><li>thromboembolic events, including arterial occlusion resulting in loss of limb, cerebrovascular accident, pulmonary embolism, pulmonary infarction, and venous thrombophlebitis, with and without concomitant ovarian hyperstimulation syndrome, have been reported<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"367260-s-3-11","title":"Pregnancy Category","mono":"X (FDA)<br\/>"},{"id":"367260-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"367260-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site reaction (2% to 8.3%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal fullness, Abdominal pain (5% to 17.3%), Nausea (4% to 7.3%)<\/li><li><b>Neurologic:<\/b>Headache (5% to 6.2%)<\/li><li><b>Reproductive:<\/b>Multiple pregnancy<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Occlusion of artery<\/li><li><b>Hematologic:<\/b>Thromboembolic disorder<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>CVA - cerebrovascular accident due to cerebral artery occlusion<\/li><li><b>Reproductive:<\/b>Ectopic pregnancy (1%), Large ovary (5% to 10%), Ovarian cancer, Ovarian hyperstimulation syndrome (2.4% to 7.2%), Torsion of the ovary, ovarian pedicle or fallopian tube<\/li><li><b>Respiratory:<\/b>Acute respiratory distress syndrome, Atelectasis, Pulmonary embolism, Pulmonary infarction<\/li><\/ul>"},"6":{"id":"367260-s-6","title":"Drug Name Info","sub":[{"id":"367260-s-6-17","title":"US Trade Names","mono":"<ul><li>Pergonal<\/li><li>Repronex<\/li><li>Menopur<\/li><\/ul>"},{"id":"367260-s-6-18","title":"Synonyms","mono":"Menotropins<br\/>"},{"id":"367260-s-6-19","title":"Class","mono":"<ul><li>Endocrine-Metabolic Agent<\/li><li>Human Follicle Stimulating Hormone<\/li><li>Human Luteinizing Hormone<\/li><\/ul>"},{"id":"367260-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},{"id":"367260-s-6-21","title":"Generic Availability","mono":"No<br\/>"}]},"7":{"id":"367260-s-7","title":"Mechanism Of Action","mono":"Follicle stimulating hormone\/luteinizing hormone (menotropins for injection) administered for 7 days up to 12 days or 20 days, produces ovarian follicular growth and maturation in women who do not have primary ovarian failure. When sufficient follicular maturation has occurred, human chorionic gonadotropin must be given to induce ovulation.<br\/>"},"8":{"id":"367260-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"367260-s-8-23","title":"Absorption","mono":"<ul><li>Intramuscular injection: time to peak concentration, (single dose) 27.5 h +\/- 25.4 h; (multiple dose) 9 h +\/- 7 h<\/li><li>Subcutaneous injection: time to peak concentration, (single dose) 17.9 h +\/- 5.8 h; (multiple dose) 8 h +\/- 3 h<\/li><li>Bioavailability: Subcutaneous route trends towards greater bioavailability than the intramuscular route<\/li><\/ul>"},"3":{"id":"367260-s-8-26","title":"Excretion","mono":"Systemic: Renal, 8% unchanged <br\/>"},"4":{"id":"367260-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Follicle stimulating hormone, single dose: (intramuscular injection) 59.2 h<\/li><li>Follicle stimulating hormone, single dose: (subcutaneous injection) 53.7 h<\/li><li>Follicle stimulating hormone, multiple dose: (intramuscular injection, subcutaneous injection) 11 h to 13 h<\/li><\/ul>"}}},"9":{"id":"367260-s-9","title":"Administration","mono":"<ul><li><b>Intramuscular<\/b><br\/><ul><li>Repronex(R): reconstitute with sterile NS<\/li><li>Repronex(R): use immediately after reconstitution and discard unused portion<\/li><\/ul><\/li><li><b>Subcutaneous<\/b><br\/><ul><li>Menopur(R) and Repronex(R): reconstitute with sterile NS<\/li><li>Menopur(R): gently swirl to mix; do not shake<\/li><li>Menopur(R) and Repronex(R): use immediately after reconstitution<\/li><li>Menopur(R): may be mixed with urofollitropin in the same syringe<\/li><li>Menopur(R) and Repronex(R): inject subQ in lower abdomen; alternate sites<\/li><\/ul><\/li><\/ul>"},"10":{"id":"367260-s-10","title":"Monitoring","mono":"<ul><li>serum progesterone, luteinizing hormone<\/li><li>estradiol levels<\/li><li>routine pelvic exam, initial endocrinologic evaluation<\/li><li>onset of ovulation<\/li><li>ovarian ultrasound day 7 and 14 (ovarian enlargement, ovarian hyperstimulation syndrome)<\/li><li>signs and symptoms of ovarian hyperstimulation syndrome (OSS), especially during first 2 weeks post-treatment<\/li><\/ul>"},"11":{"id":"367260-s-11","title":"How Supplied","mono":"<ul><li><b>Menopur<\/b><br\/>Subcutaneous Powder for Solution: (Follicle Stimulating Hormone - Luteinizing Hormone) 75 IU-75 IU<br\/><\/li><li><b>Repronex<\/b><br\/>Intramuscular Powder for Solution: (Follicle Stimulating Hormone - Luteinizing Hormone) 75 IU-75 IU<br\/><\/li><\/ul>"},"13":{"id":"367260-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise female patients of the risk of multiple births.<\/li><li>This drug may cause tachyarrhythmia, abdominal pain, bloating, diarrhea, nausea, vomiting, dizziness, dyspnea, or tachypnea. Drug may also cause gynecomastia in men.<\/li><li>Instruct female patients to report signs\/symptoms ovarian hyperstimulation syndrome (bloating, pain, or distension of abdomen, nausea, vomiting, decreased urine output).<\/li><li>Teach patient proper technique and placement of injections.<\/li><li>Advise patient to rotate injection sites.<\/li><\/ul>"}}}